Corticotropin-releasing factor receptors CRF1 and CRF 2 exert both additive and opposing influences on defensive startle behavior

Journal of Neuroscience

Volumn 24, Issue 29, 2004, Pages 6545-6552

  Risbrough, Victoria B ^a   Hauger, Richard L ^b   Roberts, Amanda L ^c   Vale, Wylie W ^d   Geyer, Mark A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Antisauvagine 30; Anxiety; CRH; NBI 30775; R121919; Urocortin

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; UROCORTIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; EMBRYO; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFORMATION PROCESSING; KNOCKOUT MOUSE; MOUSE; NEUROENDOCRINOLOGY; NEUROTRANSMISSION; NONHUMAN; PANIC; PATHOPHYSIOLOGY; PHARMACOLOGICAL PROCEDURES; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STARTLE REFLEX; STRESS;

ANIMALS; BEHAVIOR, ANIMAL; CORTICOTROPIN-RELEASING HORMONE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURAL INHIBITION; NEURONAL PLASTICITY; PEPTIDE FRAGMENTS; PYRIMIDINES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STARTLE REACTION;

EID: 3242788825     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5760-03.2004     Document Type: Article

References (87)

1. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12.
2. Bakshi VP, Kalin NH (2000) Corticotropin-releasing hormone and animal models of anxiety: gene-environment interactions. Biol Psychiatry 48:1175-1198.
3. Bakshi VP, Smith-Roe S, Newman SM, Grigoriadis DE, Kalin NH (2002) Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala. J Neurosci 22:2926-2935.
4. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, Lee KF (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24:410-414.
5. Banki CM, Bissette G, Arato M, O'Connor L, Nemeroff CB (1987) CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 144:873-877.
6. Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47:181-188.
7. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234-258.
8. Brake WG, Flores G, Francis D, Meaney MJ, Srivastava LK, Gratton A (2000) Enhanced nucleus accumbens dopamine and plasma corticosterone stress responses in adult rats with neonatal excitotoxic lesions to the medial prefrontal cortex. Neuroscience 96:687-695.
9. Brauns O, Liepold T, Radulovic J, Spiess J (2001) Pharmacological and chemical properties of astressin, antisauvagine-30 and alpha-helCRF: significance for behavioral experiments. Neuropharmacology 41:507-516.
10. Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS (1997) Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 154:624-629.
11. Brody SA, Dulawa SC, Conquet F, Geyer MA (2004) Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry 9:35-41.
12. Brown JS, Kalish HI, Farber IE (1951) Conditioned fear as revealed by magnitude of startle response to an auditory stimulus. J Exp Psychol 41:317-328.
13. Conti LH, Murry JD, Ruiz MA, Printz MP (2002) Effects of corticotropin-releasing factor on prepulse inhibition of the acoustic startle response in two rat strains. Psychopharmacology (Berl) 161:296-303.
14. Coste SC, Murray SE, Stenzel-Poore MP (2001) Animal models of CRH excess and CRH receptor deficiency display altered adaptations to stress. Peptides 22:733-741.
15. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, Hitzemann RJ, Maxson SC, Miner LL, Silva AJ, Wehner JM, Wynshaw-Boris A, Paylor R (1997) Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 132:107-124.
16. Dautzenberg FM, Hauger RL (2002) The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23:71-77.
17. Dautzenberg FM, Kilpatrick GJ, Wille S, Hauger RL (1999) The ligand-selective domains of corticotropin-releasing factor type 1 1type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile. J Neurochem 73:821-829.
18. Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G (2001) Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences. J Pharmacol Exp Ther 296:113-120.
19. Davis M, Walker DL, Lee Y (1997) Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Ann NY Acad Sci 821:305-331.
20. Dirks A, Groenink L, Schipholt MI, van der Gugten J, Hijzen TH, Geyer MA, Olivier B (2002) Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biol Psychiatry 51:583-590.
21. Dirks A, Groenink L, Westphal KG, Olivier JD, Verdouw PM, Van Der Gugten J, Geyer MA, Olivier B (2003) Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by anti-psychotic drugs. Neuropsychopharmacology 28:1790-1798.
22. Eliava M, Yilmazer-Hanke D, Asan E (2003) Interrelations between mono-aminergic afferents and corticotropin-releasing factor-immunoreactive neurons in the rat central amygdaloid nucleus: ultrastructural evidence for dopaminergic control of amygdaloid stress systems. Histochem Cell Biol 120:183-197.
23. Faraday MM (2002) Rat sex and strain differences in responses to stress. Physiol Behav 75:507-522.
24. Fendt M (1998) Different regions of the periaqueductal grey are involved differently in the expression and conditioned inhibition of fear-potentiated startle. Eur J Neurosci 10:3876-3884.
25. Frederiksen SO, Ekman R, Gottfries CG, Widerlov E, Jonsson S (1991) Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr Scand 83:273-277.
26. Geyer MA, Braff DL (1987) Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull 13:643-668.
27. Geyer MA, Dulawa SC (2003) Assessment of murine startle reactivity, prepulse inhibition, and habituation. In: Current protocols in neuroscience (Crawley JN, Skolnick P, eds), pp 8.17.11-18.17.15. New York: Wiley.
28. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154.
29. Geyer MA, McIlwain KL, Paylor R (2002) Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry 7:1039-1053.
30. Gillette GM, Skinner RD, Rasco LM, Fielstein EM, Davis DH, Pawelak JE, Freeman TW, Karson CN, Boop FA, Garcia-Rill E (1997) Combat veterans with posttraumatic stress disorder exhibit decreased habituation of the P 1 midlatency auditory evoked potential. Life Sci 61:1421-1434.
31. Graham FK (1975) Presidential Address, 1974. The more or less startling effects of weak prestimulation. Psychophysiology 12:238-248.
32. Grillon C, Morgan CA, Southwick SM, Davis M, Charney DS (1996) Base-line startle amplitude and prepulse inhibition in Vietnam veterans with posttraumatic stress disorder. Psychiatry Res 64:169-178.
33. Grillon C, Morgan III CA, Davis M, Southwick SM (1998) Effects of experimental context and explicit threat cues on acoustic startle in Vietnam veterans with posttraumatic stress disorder. Biol Psychiatry 44:1027-1036.
34. Hammack SE, Richey KJ, Schmid MJ, LoPresti ML, Watkins LR, Maier SF (2002) The role of corticotropin-releasing hormone in the dorsal raphe nucleus in mediating the behavioral consequences of uncontrollable stress. J Neurosci 22:1020-1026.
35. Hammack SE, Schmid MJ, LoPresti ML, Der-Avakian A, Pellymounter MA, Foster AC, Watkins LR, Maier SF (2003) Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress. J Neurosci 23:1019-1025.
36. 125I-Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors. Neuropharmacology 40:114-122.
37. Hoffman HS, Ison JR (1980) Reflex modification in the domain of startle. I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev 87:175-189.
38. Holsboer F, von Bardeleben U, Buller R, Heuser I, Steiger A (1987) Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. Horm Metab Res Suppl 16:80-88.
39. Jones DN, Kortekaas R, Hatcher PD, Middlemiss DN, White A, Hagan JJ (1999) Influence of peptide CRF receptor antagonists upon the behavioural effects of human/rat CRF. Eur J Pharmacol 373:141-145.
40. Kalivas PW, Duffy P, Latimer LG (1987) Neurochemical and behavioral effects of corticotropin-releasing factor in the ventral tegmental area of the rat. J Pharmacol Exp Ther 242:757-763.
41. Keedwell PA, Kumari V, Poon L, Marshall EJ, Checkley SA (2001) Information processing deficits in withdrawing alcoholics. Addict Biol 6:239-245.
42. Kirby LG, Rice KC, Valentino RJ (2000) Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology 22:148-162.
43. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, Hermanson O, Rosenfeld MG, Spiess J (2000) Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24:415-419.
44. Koob GF, Heinrichs SC (1999) A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 848:141-152.
45. Lammers CH, Garcia-Borreguero D, Schmider J, Gotthardt U, Dettling M, Holsboer F, Heuser IJ (1995) Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls. II. Biol Psychiatry 38:803-807.
46. Lang PJ, Bradley MM, Cuthbert BN (1990) Emotion, attention, and the startle reflex. Psychol Rev97:377-395.
47. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98:7570-7575.
48. Lowry CA, Rodda JE, Lightman SL, Ingram CD (2000) Corticotropin-releasing factor increases in vitro firing rates of serotonergic neurons in the rat dorsal raphe nucleus: evidence for activation of a topographically organized mesolimbocortical serotonergic system. J Neurosci 20:7728-7736.
49. Lu L, Liu Z, Huang M, Zhang Z (2003) Dopamine-dependent responses to cocaine depend on corticotropin-releasing factor receptor subtypes. J Neurochem 84:1378-1386.
50. Ludewig S, Ludewig K, Geyer MA, Hell D, Vollenweider FX (2002) Prepulse inhibition deficits in patients with panic disorder. Depress Anxiety 15:55-60.
51. Merali Z, McIntosh J, Kent P, Michaud D, Anisman H (1998) Aversive and appetitive events evoke the release of corticotropin-releasing hormone and bombesin-like peptides at the central nucleus of the amygdala. J Neurosci 18:4758-4766.
52. Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF, Weiss F (1995) Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 15:5439-5447.
53. Miyazato H, Skinner RD, Garcia-Rill E (2000) Locus coeruleus involvement in the effects of immobilization stress on the p 13 midlatency auditory evoked potential in the rat. Prog Neuropsychopharmacol Biol Psychiatry 24:1177-1201.
54. Musselman DL, Nemeroff CB (2003) Neuropeptides and hypothalamic releasing factors in psychiatric illness. In: Psychoneuroendocrinology (Wolkowitz OM, Rothschild AJ, eds), pp 29-82. Washington, DC: American Psychiatric Publishing.
55. Norris C, Blumenthal T (1996) A relationship between inhibition of the acoustic startle response and the protection of prepulse processing. Psychobiology 24:160-168.
56. Overstreet DH, Knapp DJ, Breese GR (2004) Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. Pharmacol Biochem Behav 77:405-413.
57. Pelleymounter MA, Joppa M, Ling N, Foster AC (2002) Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther 302:145-152.
58. Pernar L, Curtis AL, Vale WW, Rivier JE, Valentino RJ (2004) Selective activation of corticotropin-releasing factor-2 receptors on neurochemically identified neurons in the rat dorsal raphe nucleus reveals dual actions. J Neurosci 24:1305-1311.
59. Perrin MH, Vale WW (1999) Corticotropin releasing factor receptors and their ligand family. Ann NY Acad Sci 885:312-328.
60. Pilz PK, Schnitzler HU (1996) Habituation and sensitization of the acoustic startle response in rats: amplitude, threshold, and latency measures. Neurobiol Learn Mem 66:67-79.
61. Price ML, Curtis AL, Kirby LG, Valentino RJ, Lucki I (1998) Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology 18:492-502.
62. Radulovic J, Ruhmann A, Liepold T, Spiess J (1999) Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 19:5016-5025.
63. Rassnick S, Koob GF, Geyer MA (1992) Responding to acoustic startle during chronic ethanol intoxication and withdrawal. Psychopharmacology (Berl) 106:351-358.
64. Reul JM, Holsboer F (2002) Corticotropin-releasing factor receptors land 2 in anxiety and depression. Curr Opin Pharmacol 2:23-33.
65. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE (2001) UrocortinIl: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98:2843-2848.
66. Risbrough VB, Hauger RL, Pelleymounter MA, Geyer MA (2003) Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) 170:178-187.
67. Rivier J, Spiess J, Vale W (1983) Characterization of rat hypothalamic corticotropin-releasing factor. Proc Natl Acad Sci USA 80:4851-4855.
68. Rivier J, Gulyas J, Kirby D, Low W, Perrin MH, Kunitake K, DiGruccio M, Vaughan J, Reubi JC, Waser B, Koerber SC, Martinez V, Wang L, Tache Y, Vale W (2002) Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem 45:4737-4747.
69. Sautter FJ, Bissette G, Wiley J, Manguno-Mire G, Schoenbachler B, Myers L, Johnson JE, Cerbone A, Malaspina D (2003) Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry 54:1382-1388.
70. Sipes TA, Geyer MA (1995) 8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100,135 and localization of site of faction. Psychopharmacology (Berl) 117:41-48.
71. Sipos ML, Bauman RA, Widholm JJ, Kant GJ (2000) Behavioral effects Of 8-OH-DPAT in chronically stressed male and female rats. Pharmacol Biochem Behav 66:403-411.
72. Skinner RD, Rasco LM, Fitzgerald J, Karson CN, Matthew M, Williams DK, Garcia-Rili E (1999) Reduced sensory gating of the P1 potential in rape victims and combat veterans with posttraumatic stress disorder. Depress Anxiety 9:122-130.
73. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee KF (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093-1102.
74. Spina MG, Basso AM, Zorrilla EP, Heyser CJ, Rivier J, Vale W, Merlo-Pich E, Koob GF (2000) Behavioral effects of central administration of the novel CRF antagonist astressin in rats. Neuropsychopharmacology 22:230-239.
75. Swerdlow NR, Geyer MA, Vale WW, Koob GF (1986) Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology (Berl) 88:147-152.
76. Swerdlow NR, Geyer MA, Blumenthal T, Hartman PL (1999) Effects of discrete acoustic prestimuli on perceived intensity and behavioral responses to startling acoustic and tactile stimuli. Psychobiology 27:547-556.
77. Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 156:194-215.
78. Swerdlow NR, Shoemaker JM, Auerbach PP, Pitcher L, Goins J, Platten A (2003) Heritable differences in the dopaminergic regulation of sensorimotor gating. II. Temporal, pharmacologic and generational analyses of apomorphine effects on prepulse inhibition. Psychopharmacology (Berl). May 21, in press.
79. Takahashi LK, Ho SP, Livanov V, Graciani N, Arneric SP (2001) Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 902:135-142.
80. Valdez GR, Inoue K, Koob GF, Rivier J, Vale W, Zorrilla EP (2002) Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res 943:142-150.
81. Valdez GR, Zorrilla EP, Rivier J, Vale WW, Koob GF (2003) Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res 980:206-212.
82. Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213:1394-1397.
83. Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS, Perrin M, Vale W, Sawchenko PE (2000) Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428:191-212.
84. Wang X, Su H, Copenhagen LD, Vaishnav S, Pieri F, Shope CD, Brownell WE, De Biasi M, Paylor R, Bradley A (2002) Urocortin-deficient mice display normal stress-induced anxiety behavior and autonomic control but an impaired acoustic startle response. Mol Cell Biol 22:6605-6610.
85. Xing GQ, Russell S, Webster MJ, Post RM (2004) Decreased expression of mineralocorticoid receptor mRNA in the prefrontal cortex in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol 7:143-153.
86. Yeomans JS, Frankland PW (1995) The acoustic startle reflex: neurons and connections. Brain Res Brain Res Rev 21:301-314.
87. Yeomans JS, Li L, Scott BW, Frankland PW (2002) Tactile, acoustic and vestibular systems sum to elicit the startle reflex. Neurosci Biobehav Rev 26:1-11.